KNSA · Kiniksa Pharmaceuticals International, plc · Earnings Calls, Transcripts & Webcasts
$93.90
+0.36 (+0.38%)
At close · Nov 20
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$7.38B
Shares
78.57M
Volume · Nov 20
545.23K
Avg daily vol (3M)
658.72K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Kiniksa Pharmaceuticals International, plc Webcasts
Earnings calls, investor updates, investor days and conferences for Kiniksa Pharmaceuticals International, plc (KNSA), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-11-16
Kiniksa Pharmaceuticals International, plc (KNSA) November 16, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-10-27
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2026 Earnings Call Transcript
Confident tone
Penetration and market expansion
Financial strength and profitability
KPL-387 clinical development
Revenue
$285.97M
▲ 58.1% YoY Diluted EPS
$0.56
▲ 143.5% YoY Gross margin
90.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-09
Kiniksa Pharmaceuticals International, plc (KNSA) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-08-12
Kiniksa Pharmaceuticals International, plc (KNSA) August 12, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-07-28
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2026 Earnings Call Transcript
Confident tone
KPL-387 Phase 3 advancement
ARCALIST commercial momentum
ACC clinical guidelines dissemination
Revenue
$243.60M
▲ 55.4% YoY Diluted EPS
$0.30
▲ 30.4% YoY Gross margin
90.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Investor Update
Investor event
2026-07-28
Kiniksa Pharmaceuticals International, plc (KNSA) July 28, 2026 Investor Update
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-09
Kiniksa Pharmaceuticals International, plc (KNSA) June 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-03
Kiniksa Pharmaceuticals International, plc (KNSA) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-04-28
Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2026 Earnings Call
Revenue
$214.27M
▲ 55.5% YoY Diluted EPS
$0.27
▲ 145.5% YoY Gross margin
90.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-24
Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2025 Earnings Call Transcript
Confident tone
ARCALYST commercial growth
KPL-1161 early pipeline
KPL-387 pipeline development
Revenue
$202.13M*
▲ 65% YoY Gross margin
89.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-28
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2025 Earnings Call Transcript
Confident tone
Patient Adherence and Duration of Therapy
ARCALYST Commercial Growth
Recurrent Pericarditis Market Penetration
Revenue
$180.85M
▲ 61.2% YoY Diluted EPS
$0.23
Gross margin
88.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-29
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2025 Earnings Call Transcript
Confident tone
ARCALYST commercial execution
KPL-387 pipeline (recurrent pericarditis)
Recurrent pericarditis market leadership
Revenue
$156.80M
▲ 44.3% YoY Diluted EPS
$0.23
Gross margin
88.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-04-29
Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2025 Earnings Call Transcript
Confident tone
ARCALYST commercial performance and guidance raise
KPL-387 pipeline development in recurrent pericarditis
Medicare Part D / IRA affordability changes
Revenue
$137.78M
▲ 72.5% YoY Diluted EPS
$0.11
Gross margin
87.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-25
Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2024 Earnings Call Transcript
Confident tone
KPL-387 program announcement
ARCALYST commercial growth
Pipeline portfolio prioritization
Revenue
$122.54M*
▲ 46.9% YoY Gross margin
85.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-29
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2024 Earnings Call Transcript
Confident tone
ARCALYST commercial execution
First recurrence (earlier-line) prescribing
Abiprubart pipeline in Sjogren's disease
Revenue
$112.21M
▲ 67.4% YoY Diluted EPS
$-0.18
Gross margin
82.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-07-23
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2024 Earnings Call Transcript
Confident tone
ARCALYST commercial performance
Abiprubart pipeline / Sjögren's Phase 2b
Guidance and outlook
Revenue
$108.63M
▲ 52% YoY Diluted EPS
$-0.06
▼ 128.6% YoY Gross margin
88.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-04-23
Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2024 Earnings Call Transcript
Confident tone
ARCALYST commercial performance
Abiprubart pipeline / Sjögren's Disease
RESONANCE Registry and steroid-sparing paradigm
Revenue
$79.86M
▲ 65.2% YoY Diluted EPS
$-0.25
Gross margin
86.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2023 Earnings Call Transcript
Confident tone
ARCALYST commercial performance
Abiprubart Phase II clinical data
Abiprubart Phase IIb in new indication
Revenue
$83.39M*
▲ 34.8% YoY Gross margin
88.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-10-31
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2023 Earnings Call Transcript
Revenue
$67.05M
▼ 32.4% YoY Diluted EPS
$-0.20
▼ 106.3% YoY Gross margin
86.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-07-25
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2023 Earnings Call Transcript
Revenue
$71.47M
▲ 165% YoY Diluted EPS
$0.21
Gross margin
89.2%
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-02
Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2023 Earnings Call Transcript
Revenue
$48.34M
▲ 50.2% YoY Diluted EPS
$-0.18
Gross margin
85.4%
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2022 Earnings Call Transcript
Revenue
$61.88M*
Rev · 5q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-01
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2022 Earnings Call Transcript
Revenue
$99.14M
▲ 719.6% YoY Diluted EPS
$3.18
Gross margin
93.0%
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2022 Earnings Call Transcript
Revenue
$26.97M
▲ 250.1% YoY Diluted EPS
$-0.29
Gross margin
81.4%
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-03
Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2022 Earnings Call Transcript
Revenue
$32.19M
Diluted EPS
$-0.36
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-22
Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2021 Earnings Call Transcript
Net income
−$36.33M*
Rev · 2q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-01
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2021 Earnings Call Transcript
Revenue
$12.10M
Diluted EPS
$-0.44
Gross margin
77.1%
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2021 Earnings Call Transcript
Revenue
$7.70M
Diluted EPS
$-0.61
Gross margin
68.0%
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-01-13
Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2019 Earnings Call
Net income
−$31.80M*
Audio
Transcript
Slides
8-K10-K
Showing 1–29 of 29 webcasts
Key facts
CIK
1730430
CUSIP
G52694109
13F (30d)
280 filings
272 filers
Visit website
Investor relations